U.S. Robotics Stocks Gain as Physical AI, Surgical Competition, and Defense Autonomy Accelerate

Humanoid robots are making meaningful progress in autonomy, dexterity and repetitive real-world tasks, but widespread commercial deployment remains a work in progress, according to a report published Wednesday by Citrini Research. After a week meeting robotics labs, engineers and investors across the San Francisco Bay Area, the firm found most humanoid robots remain in development, training and tele-operated demonstrations, with real-world deployments closer to pilots than clear return-on-investment opportunities. The report examined whether robotics is approaching its own ChatGPT moment and highlighted advances from GeneralistAI and Skild AI, along with Figure AI's demonstration involving 250,000 packages, suggesting the field may advance through a mosaic of signals rather than one defining breakthrough. Basic humanoid locomotion is effectively a solved problem while complex dexterity remains more difficult, and simple repetitive tasks are already trainable. Investment in the broader robotics infrastructure is keeping pace: Tesla Inc has been preparing production lines for Optimus, XPeng Inc has launched an automated production line for its IRON humanoid robot, and Figure AI is securing access to up to 100,000 Vera Rubin GPUs from NVIDIA Corp to train the models powering its humanoid robots. The report concluded robotic autonomy is developing along a curve rather than arriving through one decisive breakthrough, with broad generalizability remaining the longer-term goal.

Tesla and SpaceX are seeking a federal ruling that the Terafab name does not infringe trademark rights held by TERA-print, adding a legal fight to the company's planned $16.8 billion chip complex. Tesla filed three Terafab-related trademark applications in May, and the planned Texas operation would manufacture, package and test advanced logic and memory chips for Optimus robots, Cybercabs and SpaceX data centers. Tesla shares slipped roughly 1% to $362.84 on Friday. The stock trades 8.66% above its $333.92 GF Value, indicating investors still pay a premium for Tesla's long-term growth ambitions. The larger question is whether Tesla can turn the $16.8 billion capital commitment into reliable semiconductor output, since bringing chip production in-house adds execution risk around yields, utilization, engineering talent and manufacturing discipline.